share_log

Wedbush Maintains Outperform on Astria Therapeutics, Raises Price Target to $22

Wedbush Maintains Outperform on Astria Therapeutics, Raises Price Target to $22

Wedbush维持Astria Therapeutics的跑赢大盘,将目标股价上调至22美元
Moomoo 24/7 ·  03/26 09:34

Wedbush analyst Laura Chico maintains Astria Therapeutics (NASDAQ:ATXS) with a Outperform and raises the price target from $17 to $22.

Wedbush分析师劳拉·奇科维持Astria Therapeutics(纳斯达克股票代码:ATXS)的表现跑赢大盘,并将目标股价从17美元上调至22美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发